<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>6158841</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">30257698</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">6158841</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="publisher-id">1317</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.1186/s12974-018-1317-z</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Demographic characteristics of the PD patients and normal controls</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1</label><caption><p>Demographic characteristics of the PD patients and normal controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th rowspan="2">Normal group (<italic>n</italic> = 29)</th><th colspan="3">Patients with PD (<italic>n</italic> = 41)</th><th rowspan="2"><italic>F</italic>†</th><th rowspan="2"><italic>P</italic>† value</th></tr><tr><th>PDN (<italic>n</italic> = 16)</th><th>PDMCI (<italic>n</italic> = 13)</th><th>PDD (<italic>n</italic> = 12)</th></tr></thead><tbody><tr><td>Sex (male/female)</td><td>13/16</td><td>8/8</td><td>7/6</td><td>6/6</td><td/><td>0.954</td></tr><tr><td>Age</td><td>62.17 ± 4.82</td><td>61.44 ± 7.33</td><td>61.54 ± 7.52</td><td>64.50 ± 5.65</td><td>0.690</td><td>0.561</td></tr><tr><td>Education</td><td>9.93 ± 4.05</td><td>11.94 ± 4.17 #</td><td>9.08 ± 3.62</td><td>5.67 ± 4.01 #</td><td>5.169</td><td><italic>0.003†</italic></td></tr><tr><td>Disease duration</td><td/><td>2.33 ± 1.38 #</td><td>2.44 ± 2.19</td><td>5.65 ± 5.32 #</td><td>4.340</td><td><italic>0.020†</italic></td></tr><tr><td>Medicine dose</td><td/><td>261.38 ± 151.91 #</td><td>413.25 ± 283.20</td><td>512.75 ± 317.41 #</td><td>3.739</td><td><italic>0.034†</italic></td></tr><tr><td>MMSE</td><td/><td>26.69 ± 3.59 #</td><td>27.31 ± 1.55 §</td><td>19.75 ± 3.60 #§</td><td>21.416</td><td><italic>0.000†</italic></td></tr><tr><td>UPDRS I</td><td/><td>2.69 ± 2.24 #</td><td>3.00 ± 2.61</td><td>5.08 ± 3.34 #</td><td>3.722</td><td><italic>0.034†</italic></td></tr><tr><td>UPDRS II</td><td/><td>9.00 ± 6.36</td><td>10.54 ± 9.00</td><td>13.33 ± 9.38</td><td>0.843</td><td>0.439</td></tr><tr><td>UPDRS III</td><td/><td>18.06 ± 13.24</td><td>26.00 ± 17.92</td><td>31.50 ± 19.94</td><td>2.042</td><td>0.145</td></tr><tr><td>UPDRS total</td><td/><td>29.75 ± 20.49</td><td>39.54 ± 28.60</td><td>49.92 ± 31.25</td><td>1.832</td><td>0.175</td></tr><tr><td>H&amp;Y score</td><td/><td>1.94 ± 1.24</td><td>2.27 ± 1.07</td><td>2.54 ± 1.01</td><td>0.710</td><td>0.499</td></tr><tr><td>S&amp;E score</td><td/><td>83.75 ± 18.93</td><td>83.08 ± 21.36</td><td>77.50 ± 18.65</td><td>0.300</td><td>0.743</td></tr><tr><td colspan="7">Oxidation parameters</td></tr><tr><td> Monocyte LFA-1</td><td>13.21 ± 4.34 ¤*</td><td>17.83 ± 5.58 ¤</td><td>17.67 ± 6.20</td><td>18.69 ± 6.02*</td><td>4.562</td><td><italic>0.006†</italic></td></tr><tr><td> Lymphocyte LFA-1</td><td>12.31 ± 3.10 ¤</td><td>15.37 ± 4.00 ¤</td><td>14.72 ± 1.78</td><td>14.43 ± 3.17</td><td>4.250</td><td><italic>0.008†</italic></td></tr><tr><td> Granulocyte LFA-1</td><td>5.42 ± 1.34</td><td>6.11 ± 1.17</td><td>6.15 ± 0.72</td><td>6.29 ± 1.69</td><td>1.841</td><td>0.149</td></tr><tr><td> Monocyte Mac-1</td><td>40.26 ± 30.28</td><td>49.69 ± 19.87</td><td>63.75 ± 53.22</td><td>52.90 ± 28.68</td><td>1.575</td><td>0.204</td></tr><tr><td> Lymphocyte Mac-1</td><td>9.91 ± 1.89</td><td>10.03 ± 2.66</td><td>10.94 ± 5.24</td><td>10.58 ± 2.37</td><td>0.477</td><td>0.699</td></tr><tr><td> Granulocyte Mac-1</td><td>41.42 ± 15.35</td><td>49.66 ± 20.81</td><td>56.41 ± 25.01</td><td>50.71 ± 27.27</td><td>1.921</td><td>0.135</td></tr><tr><td> Monocyte APO2.7 (%)</td><td>2.28 ± 1.30 ¤</td><td>8.00 ± 9.82 ¤</td><td>4.13 ± 3.44</td><td>4.83 ± 4.52</td><td>4.361</td><td><italic>0.007†</italic></td></tr><tr><td> Lymphocyte APO2.7 (%)</td><td>0.48 ± 0.38 ¤</td><td>1.04 ± 0.71 ¤</td><td>0.56 ± 0.38</td><td>0.62 ± 0.41</td><td>5.305</td><td><italic>0.002†</italic></td></tr><tr><td> Granulocyte APO2.7 (%)</td><td>0.82 ± 0.58</td><td>1.03 ± 0.57</td><td>1.17 ± 1.19</td><td>1.11 ± 0.79</td><td>0.799</td><td>0.499</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean ± standard deviation. Sex data were compared by Pearson chi-square test. Age data were compared by independent <italic>t</italic> test. Education year, oxidation parameters, clinical severity score, medication, and cognitive function data were compared by analysis of covariance (ANCOVA) after controlling for age and sex. <italic>F</italic>† and <italic>P</italic>† represent the comparison amounts of the PDN, PDMCI, and PDD patients and the normal control group, controlling for age and sex, with Bonferroni correction</p><p>¤ Significant differences between NC and PDN; * Significant differences between NC and PDD; # Significant differences between PDN and PDD; § Significant differences between PDMCI and PDD; †Significant differences among groups</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic characteristics of the PD patients and normal controls</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th rowspan="2">Normal group (n = 29)</th><th colspan="3">Patients with PD (n = 41)</th><th rowspan="2">F†</th><th rowspan="2">P† value</th></tr><tr><th>PDN (n = 16)</th><th>PDMCI (n = 13)</th><th>PDD (n = 12)</th></tr></thead><tbody><tr><td>Sex (male/female)</td><td>13/16</td><td>8/8</td><td>7/6</td><td>6/6</td><td/><td>0.954</td></tr><tr><td>Age</td><td>62.17 ± 4.82</td><td>61.44 ± 7.33</td><td>61.54 ± 7.52</td><td>64.50 ± 5.65</td><td>0.690</td><td>0.561</td></tr><tr><td>Education</td><td>9.93 ± 4.05</td><td>11.94 ± 4.17 #</td><td>9.08 ± 3.62</td><td>5.67 ± 4.01 #</td><td>5.169</td><td>0.003†</td></tr><tr><td>Disease duration</td><td/><td>2.33 ± 1.38 #</td><td>2.44 ± 2.19</td><td>5.65 ± 5.32 #</td><td>4.340</td><td>0.020†</td></tr><tr><td>Medicine dose</td><td/><td>261.38 ± 151.91 #</td><td>413.25 ± 283.20</td><td>512.75 ± 317.41 #</td><td>3.739</td><td>0.034†</td></tr><tr><td>MMSE</td><td/><td>26.69 ± 3.59 #</td><td>27.31 ± 1.55 §</td><td>19.75 ± 3.60 #§</td><td>21.416</td><td>0.000†</td></tr><tr><td>UPDRS I</td><td/><td>2.69 ± 2.24 #</td><td>3.00 ± 2.61</td><td>5.08 ± 3.34 #</td><td>3.722</td><td>0.034†</td></tr><tr><td>UPDRS II</td><td/><td>9.00 ± 6.36</td><td>10.54 ± 9.00</td><td>13.33 ± 9.38</td><td>0.843</td><td>0.439</td></tr><tr><td>UPDRS III</td><td/><td>18.06 ± 13.24</td><td>26.00 ± 17.92</td><td>31.50 ± 19.94</td><td>2.042</td><td>0.145</td></tr><tr><td>UPDRS total</td><td/><td>29.75 ± 20.49</td><td>39.54 ± 28.60</td><td>49.92 ± 31.25</td><td>1.832</td><td>0.175</td></tr><tr><td>H&amp;Y score</td><td/><td>1.94 ± 1.24</td><td>2.27 ± 1.07</td><td>2.54 ± 1.01</td><td>0.710</td><td>0.499</td></tr><tr><td>S&amp;E score</td><td/><td>83.75 ± 18.93</td><td>83.08 ± 21.36</td><td>77.50 ± 18.65</td><td>0.300</td><td>0.743</td></tr><tr><td colspan="7">Oxidation parameters</td></tr><tr><td> Monocyte LFA-1</td><td>13.21 ± 4.34 ¤*</td><td>17.83 ± 5.58 ¤</td><td>17.67 ± 6.20</td><td>18.69 ± 6.02*</td><td>4.562</td><td>0.006†</td></tr><tr><td> Lymphocyte LFA-1</td><td>12.31 ± 3.10 ¤</td><td>15.37 ± 4.00 ¤</td><td>14.72 ± 1.78</td><td>14.43 ± 3.17</td><td>4.250</td><td>0.008†</td></tr><tr><td> Granulocyte LFA-1</td><td>5.42 ± 1.34</td><td>6.11 ± 1.17</td><td>6.15 ± 0.72</td><td>6.29 ± 1.69</td><td>1.841</td><td>0.149</td></tr><tr><td> Monocyte Mac-1</td><td>40.26 ± 30.28</td><td>49.69 ± 19.87</td><td>63.75 ± 53.22</td><td>52.90 ± 28.68</td><td>1.575</td><td>0.204</td></tr><tr><td> Lymphocyte Mac-1</td><td>9.91 ± 1.89</td><td>10.03 ± 2.66</td><td>10.94 ± 5.24</td><td>10.58 ± 2.37</td><td>0.477</td><td>0.699</td></tr><tr><td> Granulocyte Mac-1</td><td>41.42 ± 15.35</td><td>49.66 ± 20.81</td><td>56.41 ± 25.01</td><td>50.71 ± 27.27</td><td>1.921</td><td>0.135</td></tr><tr><td> Monocyte APO2.7 (%)</td><td>2.28 ± 1.30 ¤</td><td>8.00 ± 9.82 ¤</td><td>4.13 ± 3.44</td><td>4.83 ± 4.52</td><td>4.361</td><td>0.007†</td></tr><tr><td> Lymphocyte APO2.7 (%)</td><td>0.48 ± 0.38 ¤</td><td>1.04 ± 0.71 ¤</td><td>0.56 ± 0.38</td><td>0.62 ± 0.41</td><td>5.305</td><td>0.002†</td></tr><tr><td> Granulocyte APO2.7 (%)</td><td>0.82 ± 0.58</td><td>1.03 ± 0.57</td><td>1.17 ± 1.19</td><td>1.11 ± 0.79</td><td>0.799</td><td>0.499</td></tr></tbody></table></div>Data are presented as mean ± standard deviation. Sex data were compared by Pearson chi-square test. Age data were compared by independent t test. Education year, oxidation parameters, clinical severity score, medication, and cognitive function data were compared by analysis of covariance (ANCOVA) after controlling for age and sex. F† and P† represent the comparison amounts of the PDN, PDMCI, and PDD patients and the normal control group, controlling for age and sex, with Bonferroni correction¤ Significant differences between NC and PDN; * Significant differences between NC and PDD; # Significant differences between PDN and PDD; § Significant differences between PDMCI and PDD; †Significant differences among groups</transformed-table></extracted-table></extracted-tables-set>